IRCT20151227025726N15
Recruiting
Phase 3
Evaluation the efficacy and safety of Umifenovir (Arbidol) Administration in comparison with Lopinavir-ritonavir (Kaletra) in COVID-19 patients
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Enrollment
- 100
- Status
- Recruiting
- Last Updated
- 5 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Laboratory confirmed COVID\-19 with RT\-PCR
- •Oxygen saturation \< 93%
- •Fever more than 72 hours before admission
- •Bilateral pulmonary infiltration
- •Age over 18 years old
Exclusion Criteria
- •Chronic kidney disease (Stage IV and V)
- •Acute kidney injury
- •Pregnancy or breastfeeding
- •Drug allergy history
- •Chronic liver disease (Child pugh C)
- •Mild phase of COVID\-19
- •Critical phase of COVID\-19
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 3
Effect of Umifenovir in treatment of covid-19IRCT20200523047550N1Tehran University of Medical Sciences50
Completed
Phase 3
mifenovir effectiveness in the treatment of COVID-19IRCT20200322046833N1Center for Progress and Development of Iran100
Recruiting
Phase 3
Investigating the efficacy and safety of Umifenovir in controlling the symptoms of patients with COVID-19IRCT20080901001165N46Center for Progress and Development of Iran200
Recruiting
Phase 3
Evaluation the effects of Favipiravir in COVID-19 patientsCOVID-19 pneumonia.COVID-19, virus identifiedU07.1IRCT20151227025726N14Shahid Beheshti University of Medical Sciences84
Unknown
Phase 4
Umifenovir in Hospitalized COVID-19 PatientsCOVID-19NCT04350684Shahid Beheshti University of Medical Sciences40